stockrow
Friday 6 November 2026
Export OPTH’s income statement to Excel — free account
Optimi Health Corp.
OPTH Healthcare Drug Manufacturers Specialty & Generic
Optimi Health Corp.’s revenue for fiscal 2025 (year ended September 2025) was $304,800.00, up 6.39% from fiscal 2024.
2.30
0.09
−3.77%
Follow OPTH
Alert me
| Sep '24 | Jun '25 | Dec '25 | Mar '26 | |
|---|---|---|---|---|
P/S ratio |
— | 0.00 | — | 0.00 |
P/FCF ratio |
— | 0.00 | — | 0.00 |
P/Operating CF |
— | (359.30) | — | (80.63) |
P/B ratio |
— | 57.93 | — | 7.83 |
Price to Tangible BV |
— | 57.93 | — | 7.83 |
EV/Sales |
— | 0.00 | — | 0.00 |
EV/EBITDA |
— | 0.00 | — | 0.00 |
EV/Operating CF |
— | 0.00 | — | (4.78) |
EV/FCF |
— | 0.00 | — | (4.65) |
Quick Ratio |
0.07 | 0.09 | 0.07 | 0.02 |
Current Ratio |
0.38 | 0.29 | 0.12 | 0.06 |
Net Debt/EBITDA |
0.00 | 0.14 | (3.06) | (3.10) |
Debt/Assets |
0.00% | 0.00% | 25.29% | 26.60% |
Debt/Equity |
0.00 | 0.00 | 0.72 | 1.02 |
Operating CF/Net income |
0.00 | 1.38 | 0.41 | 0.22 |
Capex/Depreciation |
(0.18) | (0.02) | (0.01) | (0.05) |
Interest Coverage |
— | (5.71) | (4.59) | (5.73) |
Research and Development Expense of Revenue |
— | 0.77% | 0.00% | 39.03% |
Selling, General and Administrative Expense of Revenue |
— | 123.59% | 0.00% | 389.38% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 23.38% | 0.00% | 113.93% |
Graham Net Nets |
— | (0.01) | — | (0.34) |
Graham Number |
— | 0.00 | — | 0.00 |
Free Cash Flow Yield |
— | 0.00% | — | (24.23%) |
Revenue per Share |
— | 0.00 | 0.00 | 0.02 |
Operating CF per Share |
0.00 | (0.01) | (0.14) | (0.08) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
0.00 | (0.01) | (0.14) | (0.08) |
Cash per Share |
0.00 | 0.00 | 0.11 | 0.02 |
Shareholders Equity per Share |
0.00 | 0.06 | 1.12 | 0.80 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.00 | 0.06 | 1.12 | 0.80 |
Free Cash Flow |
(3.26) | (0.91) | (0.46) | (0.26) |
Working Capital |
(1.46) | (1.86) | (5.71) | (6.76) |
Capital Expenditures |
(0.11) | (0.01) | 0.00 | (0.01) |
Net Current Asset Value |
(2.75) | (3.85) | (5.82) | (6.86) |
EV/EBIT |
— | 0.00 | — | 0.00 |
Capex to Sales |
0.00 | 0.08 | 0.00 | 0.11 |
Price to Operating Income |
— | 0.00 | — | 0.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026